Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001808365-25-000005
Filing Date
2025-12-18
Accepted
2025-12-18 16:15:05
Documents
1
Period of Report
2025-11-21

Document Format Files

Seq Description Document Type Size
1 form4-12182025_041201.html 4  
1 form4-12182025_041201.xml 4 6602
  Complete submission text file 0001808365-25-000005.txt   8014
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Issuer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address MASS GENERAL BRIGHAM VENTURES 399 REVOLUTION DRIVE, SUITE 999 SOMERVILLE MA 02145
Business Address
Knowles Julius (Reporting) CIK: 0001808365 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39264 | Film No.: 251583250